Critical path

Jeffrey Earnhardt and the No. 26 ForeverLawn Toyota GR Supra Return at Talladega

Retrieved on: 
Tuesday, April 16, 2024
Earnhardt, FOX, SHR, Toyota Supra (J29/DB), Social media, Toyota, Creation, Talladega Superspeedway, Critical path, Sam Hunt, Black, Athlete, Ark Encounter, STR, Creation Museum, Organization

LOUISVILLE, OH, April 16, 2024 (GLOBE NEWSWIRE) -- ForeverLawn, Inc.® is excited to return to the track for the Ag-Pro 300 at the Talladega Superspeedway.

Key Points: 
  • LOUISVILLE, OH, April 16, 2024 (GLOBE NEWSWIRE) -- ForeverLawn, Inc.® is excited to return to the track for the Ag-Pro 300 at the Talladega Superspeedway.
  • “I’m amped to be headed back to ‘Dega in the Black and Green Grass Machine,” says Earnhardt.
  • 26 Toyota GR Supra for Sam Hunt Racing, which will feature the familiar Black and Green Grass Machine paint scheme.
  • Viewers can follow Jeffrey Earnhardt and the Black and Green Grass Machine on social media and by watching on FOX.

Multistakeholder Collaborations are Vital to Advancing Technologies in Parkinson's

Retrieved on: 
Thursday, July 6, 2023
Learning, Critical Path Institute, Partnership, Drug development, University, Consortium, Smartphone, Rochester, Critical path, Intelligence, Human, Associate, Assistant, Organization, University of Rochester, Parkinson's disease, Journal, CPP, Patient, Manuscript, Neurology, Chet, Digital, Pharmaceutical industry

These technologies, such as smartphones and wearable sensors, offer an opportunity for objective, frequent and remote assessment of people with Parkinson's.

Key Points: 
  • These technologies, such as smartphones and wearable sensors, offer an opportunity for objective, frequent and remote assessment of people with Parkinson's.
  • Research leaders at CHeT have joined forces with organizations and regulators through C-Path's Critical Path for Parkinson's (CPP) Consortium , a precompetitive public-private partnership.
  • The goal is to enable efficient, data-driven, and patient-centric utilization of digital health technologies to speed therapeutic development," said Adams.
  • Their advancement expedites trials, enhances intelligence, reduces costs, and ultimately accelerates the delivery of new therapies and technologies to patients."

Nature Publishes Work Demonstrating Clinical ink Technology Sensitivity to Parkinson’s Disease

Retrieved on: 
Monday, May 15, 2023
Cognition, Prevalence, Speech, Smartphone, DSM-IV codes, Neurodegenerative disease, Critical path, Biomarker, Movement, MD, Patient, Diagnosis, Trial of the century, Clinical, Pharmaceutical industry, Medical imaging, Takeda, Biogen

Winston Salem, NC, May 15, 2023 (GLOBE NEWSWIRE) -- Clinical ink , a global life science technology company, announces the publication of “Using a smartwatch and smartphone to assess early Parkinson’s disease in the WATCH-PD study” in npj Parkinson’s Disease.

Key Points: 
  • Winston Salem, NC, May 15, 2023 (GLOBE NEWSWIRE) -- Clinical ink , a global life science technology company, announces the publication of “Using a smartwatch and smartphone to assess early Parkinson’s disease in the WATCH-PD study” in npj Parkinson’s Disease.
  • Results demonstrated significant associations between the digital biomarkers developed from the wearable device and sensor data streams, and conventional clinical scoring methods used in Parkinson’s disease.
  • However, diagnosis of early Parkinson’s disease remains difficult due to complexity of symptoms,” said David Anderson, Ph.D. , Principal Scientist at Clinical ink.
  • “I am delighted that Clinical ink is taking a leadership role in clinical research applications of these novel technologies.

Shinji Tsukamoto former Amazon Vice President appointed to Global Chief Commercial Officer at Persefoni

Retrieved on: 
Tuesday, April 18, 2023
Hitachi, Advertising, IBM, Mitsui, SMBC, Internet, Critical path, Disclosure, NTT Communications, Climate change mitigation, Carbon, Amazon, SCSK, CMAP, International business, Growth, Mitsui & Co., Software, Management, Mobile phone

TEMPE, Ariz., April 18, 2023 /PRNewswire/ -- Persefoni, a global leader in climate data disclosure and management, today announced that Shinji Tsukamoto, former Vice President Asia Pacific at Amazon Ads, has been appointed as Global Chief Commercial Officer & President, APAC. Shinji will lead the company's strategic growth initiatives globally, especially both Japan and the APAC region, serving enterprises requiring carbon management and accounting software.

Key Points: 
  • TEMPE, Ariz., April 18, 2023 /PRNewswire/ -- Persefoni, a global leader in climate data disclosure and management, today announced that Shinji Tsukamoto, former Vice President Asia Pacific at Amazon Ads, has been appointed as Global Chief Commercial Officer & President, APAC.
  • Prior to Persefoni, Shinji led the launch and expansion of Amazon Japan's advertising business.
  • He first joined Amazon Ads Japan as General Manager/Director and was then appointed as Japan Country Manager after playing a key role in launching the business.
  • Previously, Shinji founded the premium travel service, DUFL Inc., in the U.S. and served as the President for International Business.

Clinical ink Selected for Global Late Phase Parkinson’s Disease Programs

Retrieved on: 
Thursday, December 15, 2022
Movement, Diagnosis, Drug discovery, Human, Movement disorders, MDS, Guest appearance, Cros, Moca, Critical path, Clinical, Research, Biomarker, PGI, Patient, CGI, Medical imaging

This late-phase clinical development program follows patients over the course of eighteen months and aims to identify measures that can detect Parkinson’s disease progression before the onset of significant symptoms.

Key Points: 
  • This late-phase clinical development program follows patients over the course of eighteen months and aims to identify measures that can detect Parkinson’s disease progression before the onset of significant symptoms.
  • By adopting Clinical ink’s BrainBaselineä platform, researchers are now able to access essential insights into Parkinson’s disease progression via remotely monitored sensor biometrics and wearable data collected passively and during fit-for-purpose active tasks.
  • Clinical ink is the global life science company that brings data, technology, and patient science together.
  • By harnessing digital data, we power sponsors, CROs, researchers, and patients to recenter decentralized trials and rewrite the clinical development experience.

Clinical ink Selected for Global Late Phase Parkinson’s Disease Programs

Retrieved on: 
Wednesday, December 14, 2022
Movement, Diagnosis, Drug discovery, Human, Movement disorders, MDS, Guest appearance, Cros, Moca, Critical path, Clinical, Research, Biomarker, PGI, Patient, CGI, Medical imaging

This late-phase clinical development program follows patients over the course of eighteen months and aims to identify measures that can detect Parkinson’s disease progression before the onset of significant symptoms.

Key Points: 
  • This late-phase clinical development program follows patients over the course of eighteen months and aims to identify measures that can detect Parkinson’s disease progression before the onset of significant symptoms.
  • By adopting Clinical ink’s BrainBaselineä platform, researchers are now able to access essential insights into Parkinson’s disease progression via remotely monitored sensor biometrics and wearable data collected passively and during fit-for-purpose active tasks.
  • Clinical ink is the global life science company that brings data, technology, and patient science together.
  • By harnessing digital data, we power sponsors, CROs, researchers, and patients to recenter decentralized trials and rewrite the clinical development experience.

C-Path Awarded FDA Grant to Establish Public-Private Partnership to Advance Treatments for Rare Neurodegenerative Diseases

Retrieved on: 
Wednesday, September 14, 2022
PPP, FDA, Clinical pharmacology, Office of Inspector General, U.S. Department of Health and Human Services, Critical Path Institute, Neurodegeneration, Food, Biomarker, Pharmacology, Data management, Partnership, Unitary state, HHS, U.S. Department of Defense Strategy for Operating in Cyberspace, Government, Patient, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Agency, Critical path, Pediatrics, Public–private partnership, Solution, Drug development, ALS, Food and Drug Administration, NIH, Pharmaceutical industry, Amyotrophic lateral sclerosis

"I am thrilled about this partnership that will strengthen collaborations between C-Path, FDA and NIH, and bring together a diverse group of stakeholders."

Key Points: 
  • "I am thrilled about this partnership that will strengthen collaborations between C-Path, FDA and NIH, and bring together a diverse group of stakeholders."
  • In June, the FDA unveiled its Action Plan for Rare Neurodegenerative Diseases including Amyotrophic Lateral Sclerosis (ALS) a five-year strategy for improving and extending the lives of people with rare neurodegenerative diseases, including ALS, by advancing the development of safe and effective medical products and facilitating patient access to novel treatments.
  • "It is an honor for C-Path to be part of this transformative partnership with FDA and NIH.
  • "This partnership with FDA and NIH will positively transform medical product development and make CP-RND a template for comprehensive and meaningful collaborative science."

“Security and Compliance in the Era of Telehealth and Virtual Care” Free Webinar on August 25 Hosted by Paubox

Retrieved on: 
Monday, August 22, 2022
ISO, Chief information officer, Memorial, ISO 27001, NIST Special Publication 800-53, CEO, Master, One Health, PCI-DSS, Portland State University, NIST, SAN, Solution, Adoption, Strategic studies, Health, API, Senior, Organization, FQHC, MetLife, Software as a service, CISSP, Atlantic blue marlin, HITRUST, MBA, GLOBE, Army of the United States, Queen, Compliance, Communication, Founder, Critical path, Risk, 1, Security, Marketing, Patient, Social science, Management, HIPAA, Geography, Norwich University

SAN FRANCISCO, Aug. 22, 2022 (GLOBE NEWSWIRE) -- Paubox , a leading provider of HIPAA compliant email and marketing solutions for healthcare organizations, will host a free webinar on Security and compliance in the era of telehealth and virtual care.

Key Points: 
  • SAN FRANCISCO, Aug. 22, 2022 (GLOBE NEWSWIRE) -- Paubox , a leading provider of HIPAA compliant email and marketing solutions for healthcare organizations, will host a free webinar on Security and compliance in the era of telehealth and virtual care.
  • Paubox, based in San Francisco, is a leader in HIPAA compliant email and marketing solutions for healthcare organizations.
  • According to G2 rankings, Paubox leads the HIPAA compliant email industry for Best Email Encryption Software and Best HIPAA Compliant Messaging Software.
  • Its suite of solutions includes Paubox Email Suite, Paubox Marketing and Paubox Email API.

Oxford Team Adopts Clinical ink's Remote Monitoring Technology for Leading-Edge Parkinson's Study

Retrieved on: 
Thursday, August 11, 2022
Guest appearance, University, Biomarker, Nuffield Department of Population Health, Drug discovery, GLOBE, Diagnosis, Technology, Clinical, Brain, Research, Patient, Engineering, Neurology, University of Oxford, Nervous system, COVID-19, Critical path, Cros, Health, Disease, Medical imaging, Pharmaceutical industry, Parkinsonism

A Sponsor grant enabled the NeuroMetrology Group to include remote or at-home data collection in the study, and work with Clinical ink.

Key Points: 
  • A Sponsor grant enabled the NeuroMetrology Group to include remote or at-home data collection in the study, and work with Clinical ink.
  • By deploying Clinical inks sophisticated, sensor and wearable technology and BrainBaseline platform, researchers are now able to gather additional data and insight into Parkinsons disease progression.
  • This feedback further proves Clinical inks commitment to engineering sophisticated, built-for-purpose sensor technology that also offers the best possible user experience.
  • Joan Severson , Chief Innovation Officer at Clinical ink, said: We are honored that our mobile and wearable technology plays an integral role in this study of Parkinsons disease at Oxford.

Cutting-Edge Research Reveals Greater Insights into Parkinson’s Disease Progression

Retrieved on: 
Monday, April 11, 2022
Life, Biomarker, Classification, Clinical, Guest appearance, Apple Watch, Cros, Research, IPhone, Technology, Data collection, Time, Awareness, GLOBE, Critical path, Patient, Pharmaceutical industry, Medical imaging

Horsham, PA, April 11, 2022 (GLOBE NEWSWIRE) -- Clinical ink, a global life science technology company, todayWorld Parkinsons Dayannounces research that strengthens its standing as a critical partner in advancing clinical development for Parkinsons disease.

Key Points: 
  • Horsham, PA, April 11, 2022 (GLOBE NEWSWIRE) -- Clinical ink, a global life science technology company, todayWorld Parkinsons Dayannounces research that strengthens its standing as a critical partner in advancing clinical development for Parkinsons disease.
  • The WATCH-PD study findings demonstrate the promise of patient-driven mobile assessments and data collection for developing digital biomarkers, showing that these yield greater insights into Parkinsons disease progression.
  • Parkinsons disease is notoriously difficult to quantify, but analysis revealed 85% accuracy in early Parkinsons classification.
  • Critically, this work demonstrates that more extensive remotely-monitored measuresgathered via mobile technology and wearableshold the potential to yield greater insights into Parkinsons disease progression.